RADNOR, PA – (PR Newswire – January 5, 2015) Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, announced that the appointment of Richard A. Baron as vice president and chief financial officer (CFO) effective today. Mr. Baron offers more than 30 years of experience in executive finance leadership for early-stage, pharmaceutical and healthcare companies.
Prior to joining Zynerba, Mr. Baron served as senior vice president and CFO of Globus Medical (NYSE:GMED), a medical device company with a market cap of more than $2 billion. He previously served as vice president, finance and chief financial officer of Avid Radiopharmaceuticals, a biotech company sold to Eli Lilly in 2011 for $300 million with milestone potential to $800 million. Mr. Baron also served as CFO for a number of life sciences companies including Animas Corporation, which was sold to Johnson & Johnson in 2007. He earned a BS in Economics, concentration in Accounting, from the Wharton School of the University of Pennsylvania.
“Rick has an exemplary track record of successfully helping emerging companies grow to the next level through strategic financing,” said Zynerba chairman and chief executive officer Armando Anido. “He will be a valued member of the Zynerba team as we rapidly approach clinical development of these novel transdermal synthetic cannabinoid candidates in the coming months and work to take the company to the next stage.”
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals is dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs using modern drug delivery technology and appropriate regulatory pathways. Zynerba is developing two therapeutic candidates based on proprietary transdermal technologies that, if successfully developed, may allow sustained, consistent and controlled delivery of therapeutic levels of cannabinoids. Transdermal delivery reduces adverse effects associated with oral dosing. ZYN001 will be studied in chronic cancer pain, fibromyalgia, and peripheral neuropathic pain utilizing a synthetically manufactured prodrug of THC in a transdermal patch to deliver THC through the skin and into the bloodstream. Zynerba expects to initiate ZYN001 Phase 1 clinical studies in 3Q 2015. ZYN002 will be studied in refractory epilepsy and osteoarthritis utilizing a proprietary gel formulated to deliver synthetically manufactured cannabidiol (CBD), a non-psychoactive cannabinoid, through the skin and into the bloodstream. Zynerba expects to initiate ZYN002 Phase 1 clinical studies in 3Q 2015. Learn more at www.zynerba.com and follow the company on Twitter at @ZynerbaPharma.
Chairman and CEO
Sage Strategic Marketing